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A B S T R A C T
Detection of circulating melanoma cells by reverse transcriptase – polymerase chain reaction (RT-PCR) is a molecular
diagnostic procedure which is used to predict prognosis in melanoma patients. The most widely used specific marker for
detection of circulating melanoma cells by RT-PCR is expression of tyrosinase gene. This procedure has shown high spec-
ificity and low threshold for detection of melanoma cells. Most of the studies have shown that prognosis is worse in pa-
tients in which circulating melanoma cells were detected. Detection of circulating melanoma cells has been studied also
as a marker for predicting response to therapy. The clinical value of this procedure is limited by the proportion of patients
with clinically confirmed distant metastases being tyrosinase negative in almost all the studies. Studies have shown that
analysis of additional markers to tyrosinase enables detection of circulating melanoma cells in a higher percentage of
melanoma patients. RT-PCR has shown a lower threshold for detection than other methods (immunohistochemistry) in
detection of melanoma metastases in lymph nodes.
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Introduction
There are two principal reasons for melanoma being a
major healthcare problem nowadays. One is the signifi-
cant increase in melanoma incidence worldwide in last
decades1,2. The other is that, in spite of intense research,
no treatment has confirmed significant influence on sur-
vival of advanced stage melanoma patients. The extent of
the healthcare problem implies the need for new, more
accurate and reliable diagnostic procedures that would
help in diagnosis, predicting prognosis and the follow-up
of melanoma patients. The detection of circulating mela-
noma cells is one such molecular-diagnostic procedure,
which is based on analysis of tumor markers.
Tumor Markers for Melanoma Diagnosis
Tumor markers can be defined as compounds the
presence or change in concentration of which are associ-
ated with the presence or the progression of tumors. Tu-
mor markers have different applications. They can be
used for screening of healthy or high-risk populations to
predict development of tumors3. For that purpose the
most widely investigated marker for melanoma are mu-
tations in cycline-dependent kinase inhibitor 2A (CDKN2A)
gene, but still the routine analysis of this marker is not
recommended4,5.
Tumor markers can be used for making diagnosis of
specific type of cancer3. For that purpose the immunohi-
stochemical analysis of tumor markers is most widely ap-
plied. Immunohistochemical analysis is applied in cases
in which the standard histopathological analysis (stain-
ing of specimens with hematoxylin and eosin) can not re-
liably confirm the diagnosis of melanoma. Immuno-
histochemical analysis is also applied for detection of
melanoma metastases in regional lymph nodes, which is
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of critical importance for predicting the course of the dis-
ease and deciding on therapy. For immunohistochemical
analysis of melanoma the most widely used markers are
HMB45 antibodies specific for gp100 protein and anti-
bodies specific for S100 protein6.
Finally, tumor markers can be used for determining
prognosis and following the course of the disease in pa-
tients who are in remission (for early detection of meta-
stases and relapse) or are receiving therapy (to follow the
response to therapy)3. For that purpose the serum tumor
markers and detection of circulating tumor cells are
most often used. The most widely applied serum mela-
nomamarkers are enzyme lactate dehydrogenase (LDH),
S100-b, and melanoma inhibitory activity (MIA)7–9. In-
creased serum concentration of LDH is included in the
American Joint Committee on Cancer (AJCC) staging in-
structions from 2002 as an independent prognostic fac-
tor10. Many other molecules are being investigated as po-
tential prognostic markers in patients with melanoma7,9
(Table 1).
The development of new cytogenetic methods (com-
parative genomic hybridization (CGH), and fluorescent
in situ hybridization (FISH)), molecular genetic methods
(e.g. loss of heterozygosity (LOH) analysis), and geno-
mics, transcriptomics and proteomics has enabled new
approaches to the analysis of tumor markers in patients
with melanoma11,12. All these methods in addition to pro-
viding new insights into processes of cancer development
and its biology also offer the possibility of analysis of
changes on the DNA and RNA level and on the whole ge-
nome, transcriptome and proteome level which can pro-
vide us with information useful for establishing diagnosis
and determining prognosis in patients withmelanoma11,12.
Detection of Circulating Melanoma Cells
– Method, Specificity and Threshold for
Detection
On the basis of the assumption that circulating mela-
noma cells are associated with the development of dis-
tant metastases, the presence of circulating melanoma
cells is investigated as a potential prognostic marker in
patients with melanoma. Nevertheless, the real biologi-
cal and clinical significance of circulating tumor cells has
not been completely revealed. It has been shown that less
then 0.1% of circulating melanoma cells develop distant
metastases13.
Before reverse-transcription – polymerase chain reac-
tion (RT-PCR) was introduced, researchers had tried to
detect circulating tumor cells using cytological and im-
munocytochemical methods14. But the threshold for de-
tection of these methods was not low enough. Only the
introduction of RT-PCR enabled reaching the threshold
for detection low enough to detect small number of circu-
lating tumor cells15. Smith et al were first to show in
1991 that circulating melanoma cells can be detected by
RT-PCR using tyrosinase mRNA as a specific marker15.
Tyrosinase (monophenol monooxygenase, EC 1.14.
18.1) is an enzyme that catalyses two important steps in
melanin biosynthesis, oxidation of 3,4-dihidrohyphenyl-
alanine (DOPA) to dopaquinone and synthesis of dopa-
chrome16 (Figure 1). Tyrosinase is specifically expressed
by melanocytes, Schwann cells and melanoma cells17,18.
Since melanocytes and Schwann cells are not normally
present in the circulation, the detection of tyrosinase
mRNA in the peripheral blood of patient with melanoma
indicates the presence of melanoma cells.
Numerous studies that followed after publication of
results by Smith et al, confirmed a low threshold for de-
tection and high specificity of this method. In the major-
ity of studies the threshold for detection was low enough
to allow for the detection of 1 to 10 melanoma cells in 10
mL of peripheral blood in the relative ratio of 1 to 10mela-
noma cells in 107 peripheral blood mononuclear cells15,19–37.
It has been shown that the threshold for detection of cir-
culating melanoma cells depends significantly on the
method used for blood sample processing. Schittek et al
compared four different blood sample processing meth-
ods which had been used in previous studies of circulat-
ing melanoma cell detection by RT-PCR20. Using direct
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TABLE 1
MOLECULES INVESTIGATED AS PROGNOSTIC IMMUNOHISTOCHEMICAL AND SERUM MARKERS IN PATIENTS WITH MELANOMA
Markers of cellular proliferation Ki-67*
Tumor suppressor genes p53*, p16*, p21*, p27*
Oncogenes c-myc*
Adhesion molecules integrins*, CD44*, MUC-18*, E-cadherin*
Molecules involved in enzymatic extracellular
matrix degradation
metalloproteinases* (MMP-1, 2, 9 and 13)
tissues inhibitors of metalloproteinases* (TIMP-1, 2 and 3)
plasminogen activators* (uPA, tPA)
Melanoma antigenes neuron-specific enolase**, lipid-associated sialic acid**,
microphthalmia-associated transcription factor*
Melanin metabolites 5-S-cysteinyldopa**, 6-hydroxy-5-methoxyindole-2-carboxylic acid**
Cytokines and cytokine receptors IL-6**, IL-8**, IL-10**, soluble IL-2 receptor**
* immunohistochemical markers, ** serum markers
isolation of RNA from total blood they could detect a
minimum of 300 melanoma cells added to a blood sample.
When erythrocytes were lysed prior to RNA isolation
they could detect a minimum of 50 melanoma cells added
to a blood sample, but only in one of five blood samples
analyzed. The lowest threshold for detection was achie-
ved when RNA was isolated from mononuclear cells that
had been isolated from blood sample using a ficoll gradi-
ent with a density of 1.077 g/mL. Using this method a
minimum of two melanoma cells was detected in 60% of
blood samples analyzed and a minimum of 40 melanoma
cells was detected in all blood samples analyzed. Chan-
ging the density of the ficoll gradient to 1.09 g/mL re-
sulted in a higher threshold for detection in comparison
with the density of 1.077 g/mL. Jung et al have also
shown that isolation of mononuclear cells in the ficoll
gradient prior to RNA isolation results in a lower thresh-
old for melanoma cell detection than direct isolation of
RNA from total blood36.
In most of the studies all blood samples from donors
that did not have melanoma were negative for tyrosina-
se, which shows high specificity of this method15,19,21–25,
27–40. Only two of 512 negative controls (healthy volun-
teers and patients with non-melanoma cancer) in 23 dif-
ferent studies analyzed in a meta-analysis by Tsao et al
were positive for tyrosinase35.
Detection of Circulating Melanoma Cells
– Clinical Application
In some studies the correlation of detection of circu-
lating melanoma cells with the stage of disease was found
(Figure 2). The proportion of patients with positive value
of marker (mostly tyrosinase) was higher in patients
with higher stage of the disease21,22,25,32,33,37,39–43 (Figure
2). Still, in some other studies the correlation of detec-
tion of circulating melanoma cells with the stage of the
disease was not found19,29,30,34,44,45. The proportion of pa-
tients positive for tyrosinase in each stage of the disease
varied significantly between studies. Tsao et al analyzed
23 different studies on 1799 patients and obtained the
following average values for percentage of patients posi-
tive for tyrosinase: 18% (95% confidence interval, 3–22%)
for patients in stage 1, 28% (95 confidence interval,
23–34%) for patients in stage 2, 30% (95% confidence in-
terval, 26–34%) for patients in stage 3, and 45% (95%
confidence interval, 41–50%) for patients in stage 4 ac-
cording to the AJCC35 (Figure 2).
The prognostic value of detection of circulating mela-
noma cells was also investigated. In most of these studies
patients positive for tyrosinase had significantly increa-
sed risk for disease recurrence and shorter survival23,26,
28–34,39,40,42–44,46. Still, some other studies did not confirm
the prognostic value of detection of circulating mela-
noma cells in patients with melanoma25,27,45.
Some studies performed on patients receiving adju-
vant therapy have shown that detection of circulating
melanoma cells can be used as a marker to follow the re-
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Fig. 1. Role for tyrosinase in melanin biosynthesis.
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Fig. 2. Percentage of melanoma patients positive for tyrosinase in
different American Joint Committee on Cancer stages. Percent-
ages were calculated from data in 23 different studies analyzed
in meta-analysis by Tsao et al.35.
sponse to therapy29,30,38,41,44,46. Reynolds et al analyzed
four markers (tyrosinase, gp100, MAGE-3 and MelanA/
MART1) for detection of circulating melanoma cells in
118 melanoma patients treated adjuvantly with poly-
valent melanoma vaccine44. Blood samples for analysis
were collected before treatment and 3, 5, and 11 months
after the initiation of treatment (after the fifth, seventh
and ninth immunization, respectively). Results of this
study have shown that therapy is associated with the
clearance of melanoma cells from the circulation (after
three and five months of therapy the proportion of pa-
tients with positive value of markers decreased by 27%
and 55%, respectively)44. The clearance of melanoma
cells from circulation during the therapy detected in this
study was associated with better prognosis44. Schmidt et
al have also shown that the proportion of patients with
positive value of markers (tyrosinase and MelanA/
MART1) is significantly lower during the adjuvant treat-
ment (interleukin-2, interferon-a2b and cisplatin) than
before the treatment38. In this study loss of expression of
markers during the treatment was not associated with
better prognosis38. Gogas et al have shown that the risk
for relapse was significantly lower in patients that were
positive for tyrosinase before adjuvant treatment (inter-
feron) and negative during and after the treatment than
in patients that were positive for tyrosinase during and
after the treatment30. Mellado et al have shown that pa-
tients with melanoma and tyrosinase mRNA detected in
blood during adjuvant interferon therapy had signifi-
cantly shorter overall and disease-free survival than mel-
anoma patients with undetected tyrosinase mRNA dur-
ing treatment29. The detection of tyrosinase mRNA in
blood before interferon treatment was not associated ei-
ther with overall or with disease-free survival in the
same study29. Koyanagi et al have shown that the detec-
tion of mRNA for microphtalmia-associated transcrip-
tion factor (MITF) as a marker for circulating melanoma
cells after adjuvant biochemotherapy (cisplatin, dacarba-
zine, vinblastine, interleukin-2, interferon, and granulo-
cyte colony-stimulating factor (G-CSF)) is a significant
independent prognostic factor for relapse-free and over-
all survival41. They have also shown that the proportion
of patients positive for MITF was significantly lower af-
ter the therapy than before the therapy in patients who
remained relapse-free during follow-up, but not in pa-
tients who had a relapse41. In another study Koyanagi et
al analyzed four markers for detection of circulating mel-
anoma cells (MelanA/MART1, PAX-3, MAGE-A3, and
GalNAc-T) in melanoma patients treated with adjuvant
biochemotherapy (cisplatin, dacarbazine, vinblastine, in-
terleukin-2, interferon, and G-CSF)46. In this study they
have shown that the proportion of patients with positive
values of marker is significantly lower after the treat-
ment than before, and that positive value of markers af-
ter the treatment (but not before the treatment) is signif-
icantly associated with shorter relapse-free and overall
survival46.
Detection of Circulating Melanoma Cells
– Negative Value of Markers in Patients
with Distant Metastases
The fact that in almost all the studies a proportion of
patients with clinically confirmed distant metastases were
negative for tyrosinase makes clinical relevance of circu-
lating melanoma cells detection disputable15,18,21,23–25,26,27,
29,32,33,35–40,43,44 (Table 2). Three different mutually non-
exclusive explanations of these results have been pro-
posed.
Reinhold et al have shown that among blood samples
taken from the same melanoma patient in 2-hours inter-
vals some were positive and some were negative for
tyrosinase26. In order to explain this result they proposed
an explanation for negative finding of tyrosinase in pe-
ripheral blood from patients with distant metastases
based on the model of the metastatic process according to
which tumor cells are shed into the bloodstream tran-
siently, in a random, discontinuous manner26. According
to this explanation, the clinical value of circulating mela-
noma cells detection could be improved by analyzing sev-
eral blood samples taken from the same patient at differ-
ent time points. However, this is difficult to carry out in
practice, because single blood samples are usually taken
during routine follow-up visits.
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TABLE 2
PROPORTION OF MELANOMA PATIENTS WITH DISTANT
METASTASES AND POSITIVE FINDING OF TYROSINASE IN
PERIPHERAL BLOOD BY REVERSE-TRANSCRIPTION –
POLYMERASE CHAIN REACTION IN DIFFERENT STUDIES
Study
Tyrosinase positive patients
with distant metastases
Number/Total number
of patients with dis-
tant metastases tested
Percen-
tage
Smith et al. (1991)15 4/6 67%
Battayani et al. (1995)31 16/32 50%
Mellado et al. (1996)32 33/35 94%
Reinhold et al. (1997)26 5/13 39%
Jung et al. (1997)36 13/50 26%
Curry et al. (1998)21 60/116 52%
Schittek et al. (1999)39 21/58 36%
Schrader et al. (2000)23 13/80 16%
Proebstle i sur. (2000)33 16/24 67%
Brownbridge et al. (2001)25 30/37 81%
Quereux et al. (2001)27 20/32 63%
Mellado et al. (2002)29 5/15 33%
Schmidt et al. (2002)38 15/35 43%
Reynolds et al. (2003)44 3/11 27%
Jin et al. (2003)37 5/9 56%
Palmieri et al. (2003)43 15/23 65%
[amija et al. (2004)24 5/13 38%
Ranieri et al. (2005)45 2/2 100%
Szenajch et al have shown that the probability of posi-
tive finding of tyrosinase in peripheral blood of mela-
noma patients increases proportionally with the number
of blood samples analyzed per patient47. Based on this
finding they speculated that melanoma cells are present
in circulation of almost all melanoma patients, but their
number is below the threshold for detection of the me-
thod47. In that case the clinical value of circulating mela-
noma cells detection could be improved if a larger volume
of blood was analyzed (around 50 mL instead of usual 5–
10 mL) or if more blood samples were analyzed per
patient47. Both of these are approaches difficult to carry
out in practice.
It is possible that a negative finding of tyrosinase in
the peripheral blood of melanoma patients with distant
metastases is the result of complete loss or a significant
decrease in the expression of tyrosinase gene in a propor-
tion of melanoma cells in the course of tumor progression
due to dedifferentiation19,39. Chen et al have found differ-
ent levels of tyrosinase expression in different melanoma
tissue specimens, a small proportion of them even being
negative48. Consequentially, the clinical value of detec-
tion of circulating melanoma cells could be improved by
analysis of additional markers to tyrosinase. Different
studies indeed have shown that the proportion of mela-
noma patients with a positive finding of circulating mela-
noma cells increased when additional markers to tyro-
sinase were analyzed. Kulik et al have shown on a group
of 80 melanoma patients that additional analysis of Me-
lanA/MART1, in comparison with tyrosinase analysis
alone, enables the detection of circulating melanoma
cells in 10% more melanoma patients19. In a study per-
formed by Schittek et al on 225 melanoma patients, 72
patients (32.0%) were positive for MelanA/MART1 or
tyrosinase, while 50 patients (22.2%) were positive for
tyrosinase, which means that additional analysis of Me-
lanA/MART1 increased the sensitivity of melanoma cells
detection by 30%39. Reynolds et al analyzed four differ-
ent markers (MelanA/MART1, gp100, MAGE3, and tyro-
sinase) in a group of 118 melanoma patients and have
shown that 10–21% (depending on a marker) patients
were positive when only one marker was examined, while
47% were positive when all four markers were exami-
ned44. Other studies have also shown that analysis of
other markers in addition to tyrosinase allows for detec-
tion of circulating melanoma cells in a larger percentage
of melanoma patients than tyrosinase analysis alo-
ne21,23,43. Hoon et al have shown that analysis of four
markers (tyrosinase, p97, MUC18, and MAGE3) is statis-
tically significantly better than analysis of tyrosinase
alone22. They have also found that the number of positive
markers was statistically significantly correlated with
the stage of disease and was a significant independent
variable for predicting disease recurrence22,42. Unlike all
these studies, Brownbridge et al have shown in a group
of 211 melanoma patients that analysis of MelanA/
MART1 in addition to tyrosinase does not allow for de-
tection of circulating melanoma cells in a larger number
of melanoma patients than tyrosinase analysis alone25.
In this study all the patients that were positive for
MelanA/MART1 were also positive for tyrosinase25.
In addition to tyrosinase and MelanA/MART1, MIA,
MAGE3, tyrosinase related protein 2 (TRP2), and MITF
have shown high specificity and low threshold for detec-
tion as markers for detection of circulating melanoma
cells by RT-PCR22–24,38,41,49.
Other molecules (MUC18, p97, and gp100) that were
analyzed as potential markers for detection of melanoma
cells by RT-PCR were found positive in healthy subjects,
which makes them unreliable as melanoma markers19,
21,22,39.
Detection of Melanoma Cells in Lymph
Nodes, Bone Marrow and Cerebrospinal
Fluid
Metastatic involvement of regional lymph nodes is an
important prognostic factor in patients with melanoma.
Histopathologically confirmed presence of metastases in
regional lymph nodes was found to be the most signifi-
cant independent prognostic factor in melanoma pa-
tients that did not have clinically evident regional lymph
node metastases50.
The usual standard procedure for detection of mela-
noma metastases in regional lymph nodes involves stain-
ing of lymph node sections with hematoxylin and eosin,
and inspection for melanoma cells under light micro-
scope (HE staining)51,52. This procedure allows for detec-
tion of a single tumor cell among 104 healthy cells51 (Ta-
ble 3). It has been shown that immunohistochemical
analysis allows for detection of regional lymph node
metastases in 20% more melanoma patients than stan-
dard histopathology (HE staining)51. The markers most
widely used for immunohistochemical analysis are S100
and gp100 (HMB-45 antibodies).
Both HE staining and immunohistochemical analysis
are based on the examination of a limited number of sec-
tions, allowing for analysis of only a small part of the
whole lymph node51. It is possible that small groups of
melanoma cells which are not present in examined sec-
tions are missed that way. This is corroborated by the
fact that a group of patients in whom no regional lymph
node metastases had been found by HE staining and
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TABLE 3
THRESHOLD FOR DETECTION OF DIFFERENT PROCEDURES
FOR DETECTION OF MELANOMA METASTASES IN LYMPH
NODES
Procedure Threshold for detection*
HE staining 104
Immunohistochemistry 105
RT-PCR 106–107
* number of normal lymphocytes between which one melanoma
cell can be detected, HE – haematoxyline-eosin, RT-PCR – re-
verse transcription-polymerase chain reaction
immunohistochemical analysis still later developed dis-
tant and/or regional lymph node metastases51,53–56. RT-
PCR has been investigated for detection of regional lymph
node metastases in melanoma patients with the aim to
single out that particular group of patients. RT-PCR al-
lows for detection of a single melanoma cell among 106 to
107 healthy cells51 (Table 3). RT-PCR method theoreti-
cally also allows for the analysis of the whole lymph node.
RT-PCR allows for the detection of regional lymph
node metastases in a significantly higher proportion of
melanoma patients than HE staining and immunohis-
tochemical analysis52–55,57–60. Patients in whom the me-
tastases have been found only by RT-PCR and not by HE
staining or immunohistochemistry had a significantly
shorter survival and higher risk of recurrence than pa-
tients in whom metastases were not found either by
RT-PCR or by HE staining and immunohistochemi-
stry52,55,59. These results indicate that RT-PCR allows for
detection of clinically relevant metastases that can not be
detected by HE staining or immunohistochemical meth-
ods.
Nevertheless, the majority of patients in whom re-
gional lymph node metastases had been detected by
RT-PCR did not have relapse, a finding which diminishes
the clinical significance of this procedure51–53,55. One ex-
planation for these results may be that sentinel lymph
nodes in which the metastases were discovered by RT-
PCR were the only one with metastases, so the sentinel
lymph node biopsy was actually a therapeutic procedure
that rendered patients free of disease51. A proportion of
positive findings of melanoma metastases in regional
lymph nodes by RT-PCR can be considered false posi-
tive51,60. In around 5% of lymph nodes benign nevus cells
that express tyrosinase gene can be found, and tyro-
sinase mRNA was analyzed as melanoma marker in most
of these studies51,60. This is one of the reasons why analy-
sis of multiple melanoma markers (tyrosianse, MelanA/
MART1, MAGE3, gp100, and others) for the detection of
melanoma metastases in regional lymph nodes by RT-
PCR is studied51,59–62.
Detection of melanoma cells in bone marrow by RT-
PCR has not shown higher sensitivity than detection of
melanoma cells in peripheral blood and has not shown
prognostic significance63–65.
In one study, analysis of tyrosinase and two other mel-
anoma markers (MAGE3, and MelanA/MART1) was
used for the detection of melanoma cells in cerebrospinal
fluid66. In this study RT-PCR analysis allowed for detec-
tion of melanoma cells in a higher proportion of patients
than cytological and immunocytochemical analysis66. In
the same study significant correlation between the detec-
tion of melanoma cells in cerebrospinal fluid by RT-PCR
and development of central nervous system metastases
in the next three months was found66.
Conclusion
RT-PCR has shown high specificity and low threshold
for detection of circulating melanoma cells, but still fur-
ther studies are needed before this method can be in-
cluded in routine clinical practice. One critical point is
the standardization of the method and markers in order
to make results obtained in different institutions fully
comparable. Other critical point is how to incorporate
this method in the treatment strategy and algorithms for
melanoma patients. Although most of the studies have
shown prognostic value of this method, it is not clear at
which point and in which patients should it be per-
formed. There are several potential clinical applications
of this method. Detection of circulating melanoma cells
could be included as a parameter in the staging of mela-
noma patients in order to better predict survival groups.
However, further studies that would confirm that detec-
tion of circulating melanoma cells is a prognostic factor
independent of clinical stage and other prognostic factors
are needed to justify such clinical application of this
method. Other potential clinical application is for follow-
ing melanoma patients after surgery. Positive finding of
circulating melanoma cells in otherwise disease free pa-
tients could indicate higher risk for metastases, and
these patients could be followed more frequently and
more thoroughly (eg. inclusion of additional radiological
procedures). Starting adjuvant therapy based on positive
finding of circulating melanoma cells is not supported by
the results published so far. Another potential clinical ap-
plication of this method is for following a response to
adjuvant therapy. Theoretically, the dosage and duration
of adjuvant therapy could be modified based on the re-
sults of circulating melanoma cells detection. However,
further studies aimed specifically at each potential clini-
cal application are needed before decision on clinical use
of this method can be made.
R E F E R E N C E S
1. FERLAY J, BRAY F, PISANI P, PARKIN DM, Globocan 2002: Can-
cer incidence, mortality and prevalence worldwide (IARC Press, Lyon,
2004). — 2. BERWICK M, WEINSTOCK MA, Epidemiology, current
trends. In: BALCH CM, HOUGHTON AN, SOBER AJ, SOONG SJ (Eds),
Cutaneous melanoma (Quality Medical Publishing, St Louis, 2003). — 3.
O’ROURKE TJ, Tumor markers. In: CALABRESI P, SCHEIN PS (Eds),
Medical oncology: basic principles and clinical management of cancer (Mc
Graw-Hill, New York, 1993). — 4. HANSEN CB, WADGE LM, LOWSTU-
TER K, BOUCHERK, LEACHMAN SA, Lancet Oncol, 5 (2004) 314. — 5.
KEFFORD RF, NEWTON BISHOP JA, BERGMAN W, TUCKER MA, J
Clin Oncol, 17 (1999) 3245. — 6. YAZIJI H, GOWN AM, Int J Surg Pa-
thol, 11 (2003) 11. — 7. LI N, MANGINI J, BHAWAN J, J Cutan Pathol,
29 (2002) 324. — 8. HARPIO R, EINARSSON R, Clin Biochem, 37 (2004)
512. — 9. UGUREL S, Hautarzt, 56 (2005) 173. — 10. BALCH CM, BU-
ZAID AC, SOONG SJ, ATKINS MB, CASCINELLI N, COIT DG, FLE-
MING ID, GERSHENWALD JE, HOUGHTON A, KIRKWOOD JM, MC-
MASTERS KM, MIHM MF, MORTON DL, REINTGEN DS, ROSS MI,
SOBER A, THOMPSON JA, THOMPSON JF, J Clin Oncol, 19 (2001)
3635. — 11. POLLOCK PA, WEERARATNA A, TRENT JM, Genetics and
molecular staging. In: BALCH CM, HOUGHTON AN, SOBER AJ,
SOONG SJ (Eds), Cutaneous melanoma (Quality Medical Publishing, St
Louis, 2003). — 12. KASHANI-SABET M, Curr Oncol Rep, 6 (2004) 401.
I. [amija et al.: Detection of Melanoma Cells by RT-PCR, Coll. Antropol. 31 (2007) 4: 1187–1194
1192
— 13. FIDLER IJ, J Natl Cancer Inst, 45 (1970) 773. — 14. JOHNSON
PW, BURCHILL SA, SELBY PJ, Br J Cancer, 72 (1995) 268. — 15.
SMITH B, SELBY P, SOUTHGATE J, PITTMANK, BRADLEY C, BLAIR
GE, Lancet, 338 (1991) 1227. — 16. HEARING VJ, JIMENEZ M, Int J
Biochem, 19 (1987) 1141. — 17. KWON BS, HAQ AK, POMERANTZ SH,
HALABAN R, Proc Natl Acad Sci USA, 84 (1987) 7473. — 18. BATTYANI
Z, XERRI L, HASSOUN J, BONERANDI JJ, GROB JJ, Pigment Cell Res,
6 (1993) 400. — 19. KULIK J, NOWECKI ZI, RUTKOWSKI P, RUKA W,
ROCHOWSKA M, SKURZAK H, SIEDLECKI JA, Melanoma Res, 11
(2001) 65. — 20. SCHITTEK B, BLAHETA HJ, FLORCHINGER G,
SAUER B, GARBE C, Br J Dermatol, 141 (1999) 37. — 21. CURRY BJ,
MYERS K, HERSEY P, J Clin Oncol, 16 (1998) 1760. — 22. HOON DS,
WANG Y, DALE PS, CONRAD AJ, SCHMID P, GARRISON D, KUO C,
FOSHAG LJ, NIZZE AJ, MORTON DL, J Clin Oncol, 13 (1995) 2109. —
23. SCHRADER AJ, PROBST-KEPPER M, GROSSE J, KUNTER U,
FRANZKE A, SEL S, ATZPODIEN E, BUER J, Anticancer Res, 20 (2000)
3619. — 24. [AMIJA I, LUKAC J, MARIC-BROZIC J, KUSIC Z, Croat
Med J, 45 (2004) 142. — 25. BROWNBRIDGE GG, GOLD J, EDWARDM,
MACKIE RM, Br J Dermatol, 144 (2001) 279. — 26. REINHOLD U,
LUDTKE-HANDJERY HC, SCHNAUTZ S, KREYSEL HW, ABKEN H, J
Invest Dermatol, 108 (1997) 166. — 27. QUEREUXG, DENISM, KHAM-
MARI A, LUSTENBERGER P, DRENO B, Dermatology, 203 (2001) 221.
— 28. OSELLA-ABATE S, SAVOIA P, QUAGLINO P, FIERRO MT, EPO-
RATI C. ORTONCELLI M. BERNENGO MG, Br J Cancer 89 (2003)
1457. — 29. MELLADO B, DEL CARMEN VELA M, COLOMER D, GU-
TIERREZ L, CASTEL T, QUINTO L, FONTANILLAS M, REGUART N,
DOMINGO-DOMENECH JM, MONTAGUT C, ESTAPE J, GASCON P, J
Clin Oncol, 20 (2002) 4032. — 30. GOGASH, KEFALA G, BAFALOUKOS
D, FRANGIA K, POLYZOS A, PECTASIDES D, TSOUTSOS D, PANA-
GIOTOU P, IOANNOVICH J, LOUKOPOULOS D, Br J Cancer, 87 (2002)
181. — 31. BATTAYANI Z, GROB JJ, XERRI L, NOE C, ZAROUR H,
HOUVAENEGHEL G, DELPERO JR, BIRMBAUMD, HASSOUN J, BO-
NERANDI JJ, Arch Dermatol, 131 (1995) 443. — 32. MELLADO B, CO-
LOMER D, CASTEL T, MUNOZ M, CARBALLO E, GALAN M, MASCA-
RO JM, VIVES-CORRONS JL, GRAU JJ, ESTAPE J, J Clin Oncol, 14
(1996) 2091. — 33. PROEBSTLE TM, JIANG W, HOGEL J, KEILHOLZ
U, WEBER L, VOIT C, Br J Cancer, 82 (2000) 118. — 34. MELLADO B,
GUTIERREZ L, CASTEL T, COLOMER D, FONTANILLAS M, CASTRO
J, ESTAPE J, Clin Cancer Res, 5 (1999) 1843. — 35. TSAO H, NADI-
MINTI U, SOBER AJ, BIGBY M, Arch Dermatol, 137 (2001) 325. — 36.
JUNG FA, BUZAID AC, ROSS MI, WOODS KV, LEE JJ, ALBITAR M,
GRIMM EA, J Clin Oncol, 15 (1997) 2826. — 37. JIN HY, YAMASHITA T,
MINAMITSUJI Y, OMORI F, JIMBOW K, J Dermatol Sci, 33 (2003) 169.
— 38. SCHMIDT H, SORENSEN BS, VON DER MAASE H, BANG C,
AGGER R, HOKLANDM, NEXO E, Melanoma Res, 12 (2002) 585. — 39.
SCHITTEK B, BODINGBAUER Y, ELLWANGER U, BLAHETA HJ,
GARBE C, Br J Dermatol, 141 (1999) 30. — 40. OSELLA-ABATE S,
QUAGLINO P, SAVOIA P, LEPORATI C, COMESSATTI A, BERNENGO
MG, Melanoma Res, 12 (2002) 325. — 41. KOYANAGI K, O’DAY SJ,
GONZALEZ R, LEWIS K, ROBINSON WA, AMATRUDA TT, KUO C,
WANG HJ, MILFORD R, MORTON DL, HOON DS, Clin Cancer Res, 12
(2006) 1137. — 42. HOON DS, BOSTICK P, KUO C, OKAMOTO T,
WANG HJ, ELASHOFF R, MORTON DL, Cancer Res, 60 (2000) 2253. —
43. PALMIERI G, ASCIERTO PA, PERRONE F, SATRIANO SM, OTTAI-
ANO A, DAPONTE A, NAPOLITANO M, CARACO C, MOZZILLO N,
MELUCCI MT, COSSU A, TANDA F, GALLO C, SATRIANO RA, CA-
STELLO G, J Clin Oncol, 21 (2003) 767. — 44. REYNOLDS SR, AL-
BRECHT J, SHAPIRO RL, ROSES DF, HARRIS MN, CONRAD A, ZELE-
NIUCH-JACQUOTTE A, BYSTRYN JC, Clin Cancer Res, 9 (2003) 1497.
— 45. RANIERI JM, WAGNER JD, WIEBKE EA, AZUAJE R, SMITH
ML, WENCK S, DAGGY J, COLEMAN JJ, Plast Reconstr Surg, 115
(2005) 1058. — 46. KOYANAGI K, O’DAY SJ, GONZALEZ R, LEWIS K,
ROBINSON WA, AMATRUDA TT, WANG HJ, ELASHOFF RM, TA-
KEUCHI H, UMETANI N, HOON DS, J Clin Oncol, 23 (2005) 8057. —
47. SZENAJCH J, JASINSKI B, KOZAK A, KULIK J, CHOMICKA M,
STRUZYNA J, NOWECKI Z, RUTKOWSKI P, RUKA W, KUPSC W, SIE-
DLECKI J, WIKTOR-JEDRZEJCZAK W, Melanoma Res, 12 (2002) 399.
— 48. CHEN YT, STOCKERT E, TSANG S, COPLAND KA, OLD LJ,
Proc Natl Acad Sci USA, 92 (1995) 8125. — 49. MUHLBAUER M, LAN-
GENBACH N, STOLZ W, HEIN R, LANDTHALER M, BUETTNER R,
BOSSERHOFF AK, Clin Cancer Res, 5 (1999) 1099. — 50. BALCH CM,
SOONG SJ, GERSHENWALD JE, THOMPSON JF, REINTGEN DS,
CASCINELLI N, URIST M, MCMASTERS KM, ROSS MI, KIRKWOOD
JM, ATKINS MB, THOMPSON JA, COIT DG, BYRD D, DESMOND R,
ZHANG Y, LIU PY, LYMAN GH, MORABITO A, J Clin Oncol, 19 (2001)
3622. — 51. REINTGEN DS, THOMPSON JF, GERSHENWALD JE. In-
traoperative mapping and sentinel node technology. In: BALCH CM,
HOUGHTON AN, SOBER AJ, SOONG SJ (Eds), Cutaneous melanoma
(Quality Medical Publishing, St Louis, 2003). — 52. SHIVERS SC, WANG
X, LI W, JOSEPH E, MESSINA J, GLASS LF, DECONTI R, CRUSE CW,
BERMAN C, FENSKE NA, LYMAN GH, REINTGEN DS, JAMA, 280
(1998) 1410. — 53. GOYDOS JS, PATEL KN, SHIH WJ, LU SE, YUDD
AP, KEMPF JS, BANCILA E, GERMINO FJ, J Am Coll Surg, 196 (2003)
196. — 54. LI W, STALL A, SHIVERS SC, LIN J, HADDAD F, MESSINA
J, GLASS LF, LYMAN G, REINTGEN DS, Ann Surg, 231 (2000) 795. —
55. ULRICH J, BONNEKOH B, BOCKELMANN R, SCHON M, SCHON
MP, STEINKE R, ROESSNER A, SCHMIDT U, GOLLNICK H, Eur J
Cancer, 40 (2004) 2812. — 56. GERSHENWALD JE, THOMPSON W,
MANSFIELD PF, LEE JE, COLOME MI, TSENG CH, LEE JJ, BALCH
CM, REINTGEN DS, ROSS MI, J Clin Oncol, 17 (1999) 976. — 57.
WANG X, HELLER R, VANVOORHIS N, CRUSE CW, GLASS F, FEN-
SKE N, BERMAN C, LEO-MESSINA J, RAPPAPORT D, WELLS K, DE-
CONTI R, MOSCINSKI L, STANKARD C, PULEO C, REINTGEN D,
Ann Surg, 220 (1994) 768. — 58. BLAHETA HJ, SCHITTEK B, BREU-
NINGER H, SOTLAR K, ELLWANGER U, THELEN MH, MACZEY E,
RASSNER G, BUELTMANN B, GARBE C, Am J Surg Pathol, 23 (1999)
822. — 59. BOSTICK PJ, MORTON DL, TURNER RR, HUYNH KT,
WANG HJ, ELASHOFF R, ESSNER R, HOON DS, J Clin Oncol, 17
(1999) 3238. — 60. RIMOLDI D, LEMOINE R, KURT AM, SALVI S,
BERSETM, MATTERM, ROCHE B, CEROTTINI JP, GUGGISBERG D,
KRISCHER J, BRAUN R, WILLI JP, ANTONESCU C, SLOSMAN D, LE-
JEUNE FJ, LIENARD D, Melanoma Res, 13 (2003) 511. — 61. MC-
MASTERS KM, Ann Surg Oncol, 8 Suppl 9 (2001) 41. — 62. TAKEUCHI
H, MORTON DL, KUO C, TURNER RR, ELASHOFF D, ELASHOFF R,
TABACK B, FUJIMOTO A, HOON DS, J Clin Oncol, 22 (2004) 2671. —
63. GHOSSEIN RA, COIT D, BRENNAN M, ZHANG ZF, WANG Y,
BHATTACHARYA S, HOUGHTON A, ROSAI J, Clin Cancer Res, 4
(1998) 419. — 64. WALDMANN V, DEICHMANN M, BOCK M, JACKEL
A, NAHER H, Br J Dermatol, 140 (1999) 1060. — 65. WALDMANN V,
WACKER J, DEICHMANN M, JACKEL A, BOCK M, NAHER H, Recent
Results Cancer Res, 158 (2001) 118. — 66. HOON DS, KUO CT, WA-
SCHER RA, FOURNIER P, WANGHJ, O’DAY SJ, J Invest Dermatol, 117
(2001) 375.
I. [amija
Department of Oncology and Nuclear Medicine, University Hospital »Sestre milosrdnice«, Vinogradska cesta 29,
10000 Zagreb, Croatia
e-mail: isamija@kbsm.hr
I. [amija et al.: Detection of Melanoma Cells by RT-PCR, Coll. Antropol. 31 (2007) 4: 1187–1194
1193
ODRE\IVANJE DISEMINIRANIH MELANOMSKIH STANICA METODOM LAN^ANE
REAKCIJE POLIMERAZOM NAKON OBRNUTOG PREPISIVANJA
S A @ E T A K
Odre|ivanje cirkuliraju}ih melanomskih stanica metodom lan~ane reakcije polimerazom nakon obrnutog prepisi-
vanja (RT-PCR) je molekularno dijagnosti~ki postupak koji se primjenjuje u bolesnika sa melanomom u svrhu predvi|a-
nja prognoze. Kao specifi~ni biljeg za odre|ivanje cirkuliraju}ih melanomskih stanica metodom RT-PCR naj~e{}e se
primjenjuje ekspresija gena za tirozinazu. Ovaj postupak je pokazao visoku specifi~nost i nizak prag detekcije melanom-
skih stanica. Ve}ina istra`ivanja je pokazala de je prognoza lo{ija u bolesnika u kojih su na|ene cirkuliraju}e melanom-
ske stanice. Odre|ivanje cirkuliraju}ih melanomskih stanica istra`uje se i kao biljeg za pra}enje odgovora ne lije~enje.
Klini~ku vrijednost ovog postupka umanjuje to {to je u gotovo svim istra`ivanjima odre|eni udio bolesnika s klini~ki
potvr|enim udaljenim metastazama bio negativan na tirozinazu. Pokazalo se da analiza dodatnih biljega uz tirozinazu
omogu}uje otkrivanje cirkuliraju}ih melanomskih stanica u ve}eg broja bolesnika sa melanomom. Metoda RT-PCR je
pokazala ni`i prag detekcije od drugih postupaka (imunohistokemije) pri odre|ivanju metastaza melanoma u limfnim
~vorovima.
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